We are monitoring the impact of COVID-19 on Europe Pharmacovigilance Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 7548
Share on
Share on

Europe Pharmacovigilance Market Research Report - Segmented By Clinical Trial Phase, Service Provider, Method & Country(UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2020 to 2025)

Pulished: February, 2020
ID: 7548
Pages: 145

Europe Pharmacovigilance Market Size (2020 to 2025)

The size of the Pharmacovigilance Market in Europe was worth USD 1.34 billion in 2020 and estimated to be growing at a CAGR of 13.9% to reach USD 2.58 billion by 2025 during the forecast period.

In 2019, the European region had the second-largest market share of the global pharmacovigilance market following North America. The EU has also developed a pharmacovigilance center called Eudra Vigilance in the area to reduce the time required for the clinical trials, which is boosting the market growth. There is a sizeable technological advancement in the field of pharmacovigilance, which is promoting the market growth. There are many biopharmaceutical companies in the region, which are doing research and development in drugs, leading to a rise in the number of clinical trials and is estimated to favor market growth. 

The pharmacovigilance system consists of different technologies where it is difficult to maintain without skilled persons. The lack of this specialized expertise is significantly hindering the demand of the market. There is a lack of technological innovation in the pharmacovigilance, impeding the need for the market in Europe. Strict rules and regulations by the government in approving new drugs are also slowly degrading the market demand. 

This research report segmented and sub-segmented into the following categories:

  • By Clinical Trial Phase: Pre-clinical, Phase I, Phase II, Phase III and Phase IV
  • By Service Provider: In-house and Contract Outsourcing
  • By Method: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining             
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and Rest of Europe.

Regional Analysis

In Europe, the United Kingdom's pharmacovigilance market is growing at a significant rate. Around 6.5% of the cases admitted in the hospital of the UK are of an adverse drug reaction; thus, there is an excellent demand for pharmacovigilance in the UK. Increasing awareness through social media is also a factor fuelling the need of the market.

The pharmacovigilance market in Germany is next in line after the United Kingdom shows a robust growth rate. Increasing incidences of chronic diseases and a rise in the demand for quality treatment services escalate the market's growth rate.

The French government is developing a pharmacovigilance system for veterinary products, which is estimated to boost the country's market.

Key players operating in the Europe Pharmacovigilance Market profiled in this report are Boehringer Ingelheim, Accenture, Bristol-Myers Squibb, Covance, ICON, PAREXEL, Quintiles, United BioSource, Synowlwedge, and Cognizant Technology Solutions Corporation.

1. Introduction     

  1.1 Market Definition      

  1.2 Study Deliverables    

  1.3 Base Currency, Base Year and Forecast Periods     

  1.4 General Study Assumptions  

2. Research Methodology 

  2.1 Introduction   

  2.2 Research Phases 

    2.2.1 Secondary Research    

    2.2.2 Primary Research 

    2.2.3 Econometric Modelling      

    2.2.4 Expert Validation  

  2.3 Analysis Design    

  2.4 Study Timeline     

3. Overview    

  3.1 Executive Summary  

  3.2 Key Inferences    

  3.3 Epidemology  

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC) 

  4.1 Market Drivers     

  4.2 Market Restraints      

  4.3 Key Challenges    

  4.4 Current Opportunities in the Market  

5. Market Segmentation    

  5.1 Clinical trial phase      

    5.1.1 Introduction    

    5.1.2 Pre-clinical 

    5.1.3 Phase I      

    5.1.4 Phase II    

    5.1.5 Phase III   

    5.1.6 Phase IV   

    5.1.7  Y-o-Y Growth Analysis, By Clinical trial phase    

    5.1.8  Market Attractiveness Analysis, By Clinical trial phase  

    5.1.9  Market Share Analysis, By Clinical trial phase   

  5.2 Service provider  

    5.2.1 Introduction    

    5.2.2 In-house  

    5.2.3 Contract outsourcing   

    5.2.4 Y-o-Y Growth Analysis, By Service provider

    5.2.5 Market Attractiveness Analysis, By Service provider     

    5.2.6 Market Share Analysis, By Service provider

  5.3 Method  

    5.3.1 Spontaneous Reporting    

    5.3.2 Intensified ADR Reporting

    5.3.3 Targeted Spontaneous Reporting 

    5.3.4 Cohort Event Monitoring  

    5.3.5 EHR Mining      

    5.3.5 Y-o-Y Growth Analysis, By Method 

    5.3.6 Market Attractiveness Analysis, By Method      

    5.3.7 Market Share Analysis, By Method       

6. Geographical Analysis    

  6.1 Introduction   

    6.1.1 Regional Trends    

    6.1.2 Impact Analysis     

    6.1.3 Y-o-Y Growth Analysis 

      6.1.3.1 By Geographical Area

      6.1.3.2 By Clinical trial phase

      6.1.3.3 By Service provider

      6.1.3.4 By Method

    6.1.4  Market Attractiveness Analysis     

      6.1.4.1 By Geographical Area

      6.1.4.2 By Clinical trial phase

      6.1.4.3 By Service provider

      6.1.4.4 By Method

    6.1.5  Market Share Analysis      

      6.1.5.1 By Geographical Area

      6.1.5.2 By Clinical trial phase

      6.1.5.3 By Service provider

      6.1.5.4 By Method

  6.2 U.K   

  6.3 Spain 

  6.4 Germany

  6.5 Italy   

  6.6 France     

7. Strategic Analysis    

  7.1 PESTLE analysis    

    7.1.1 Political     

    7.1.2 Economic 

    7.1.3 Social  

    7.1.4 Technological  

    7.1.5 Legal   

    7.1.6 Environmental

  7.2 Porter’s Five analysis  

    7.2.1 Bargaining Power of Suppliers 

    7.2.2 Bargaining Power of Consumers    

    7.2.3 Threat of New Entrants     

    7.2.4 Threat of Substitute Products and Services

    7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis     

  8.1 Boehringer Ingelheim

    8.1.1 Overview 

    8.1.2 Product Analysis   

    8.1.3 Financial analysis  

    8.1.4 Recent Developments

    8.1.5 SWOT analysis

    8.1.6 Analyst View   

  8.2 Accenture     

  8.3 Bristol-Myers Squibb  

  8.4 Covance  

  8.5 ICON 

  8.6 PAREXEL 

  8.7 Quintiles 

  8.8  United BioSource      

  8.9 Synowlwedge      

  8.10 Cognizant Technology Solutions Corporation

9. Competitive Landscape 

  9.1 Market share analysis

  9.2 Merger and Acquisition Analysis  

  9.3 Agreements, collaborations and Joint Ventures    

  9.4 New Product Launches    

10. Market Outlook and Investment Opportunities      

Appendix 

  a) List of Tables  

  b) List of Figures  

  • Regional  and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms By Service Provider Others with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

 

  1. Europe Pharmacovigilance Market, By Clinical trial phase, From 2020 to 2025 (USD Million)
  2. Europe Pre-clinical Market By Region, From 2020 to 2025 (USD Million)
  3. Europe Phase I Market By Region, From 2020 to 2025 (USD Million)
  4. Europe Phase II Market By Region, From 2020 to 2025 (USD Million)
  5. Europe Phase III Market By Region, From 2020 to 2025 (USD Million)
  6. Europe Phase IV Market By Region, From 2020 to 2025 (USD Million)
  7. Europe Pharmacovigilance Market, By Service provider, From 2020 to 2025 (USD Million)
  8. Europe In house Market By Region, From 2020 to 2025 (USD Million)
  9. Europe Contract outsourcing Market By Region, From 2020 to 2025 (USD Million)
  10. U.K. Pharmacovigilance Market, By Clinical trial phase, From 2020 to 2025 (USD Million)
  11. U.K. Pharmacovigilance Market, By Service provider, From 2020 to 2025 (USD Million)
  12. Germany Pharmacovigilance Market, By Clinical trial phase, From 2020 to 2025 (USD Million)
  13. Germany Pharmacovigilance Market, By Service provider, From 2020 to 2025 (USD Million)
  14. France Pharmacovigilance Market, By Clinical trial phase, From 2020 to 2025 (USD Million)
  15. France Pharmacovigilance Market, By Service provider, From 2020 to 2025 (USD Million)
  16. Italy Pharmacovigilance Market, By Clinical trial phase, From 2020 to 2025 (USD Million)
  17. Italy Pharmacovigilance Market, By Service provider, From 2020 to 2025 (USD Million)
  18. Spain Pharmacovigilance Market, By Clinical trial phase, From 2020 to 2025 (USD Million)
  19. Spain Pharmacovigilance Market, By Service provider, From 2020 to 2025 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample